Laddar...
Potential of liraglutide in the treatment of patients with type 2 diabetes
Liraglutide is a long-acting analog of GLP-1, being developed by Novo Nordisk and currently undergoing regulatory review for the treatment of type 2 diabetes. Upon injection, liraglutide binds non-covalently to albumin, giving it a pharmacokinetic profile suitable for once-daily administration. In c...
Sparad:
| Huvudupphovsman: | |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Dove Medical Press
2009
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2672437/ https://ncbi.nlm.nih.gov/pubmed/19436648 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|